Imugene Ltd · ASX:IMU
Imugene — Investor Presentation (March 2026)
31 slides from Imugene's investor presentation, Mar 11, 2026
Slide 1: Innovation in Cancer Treatment: Capital Raising Presentation
ASX:IMU For personal use only Innovation in Cancer Treatment Capital Raising Presentation March 2026 Release authorised by the Managing Director and Chief Executive Officer Imugene Limited 1
Slide 2: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by Imugene Limited (ASX: IMU) (Company) in connection with a two tranche non- International offer restrictions - This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United underwritt
Slide 3: Imugene is a clinical stage cancer company developing cellular therapy
For personal use only Imugene is a clinical stage cancer company developing cellular therapy 3 3
Slide 4: Executive Summary
Executive Summary Azer-cel is an off-the-shelf CAR-T therapy with compelling efficacy, regulatory clarity, and multiple capital-efficient paths to market • 82% ORR (14/17) in 3L+ DLBCL, including heavily pre-treated patients For personal use only Compelling efficacy in advanced disease • ~50% failed
Slide 5: Capital Raising Summary
Capital Raising Summary Imugene is undertaking an up to A$20 million capital raising via a non-underwritten two-tranche placement (Placement) of up to A$12 million and up to A$8 million share purchase plan (SPP) (together, the Offer) at A$0.18 per share, comprising the issue of up to approximately 1
Slide 6: Azer-cel Overview
For personal use only Azer-cel Overview 6 6
Slide 7: How is Imugene different? Allogeneic vs Autologous CAR-T
How is Imugene different? Allogeneic vs Autologous CAR-T Allogeneic CAR-T Cell Therapy is significantly differentiated from approved Autologous CAR-T therapies on cost and wait times Autologous Allogeneic Autologous Allogeneic For personal use only Overview • Autologous CAR-T cells • Dose for multip
Slide 8: Introducing azer-cel
Introducing azer-cel Imugene’s potential first-in-class, off-the-shelf Allogeneic CAR-T Cell Therapy, with initial indications in Autologous CAR-T failed DLBCL and several CAR-T naïve lymphomas 1 For personal use only “Off-the-shelf” CD19 Allogeneic CAR-T 1. Collection from healthy donor 2 Addresses
Slide 9: Azer-cel Commercialization Opportunity
Azer-cel Commercialization Opportunity $3bn+ p.a. US potential market opportunity in rare & niche indications and 3L+ DLBCL AZER CEL US INCIDENCE 1 ELIGIBLE FOR CAR-T 2 MARKET OPPORTUNITY 3 MZL For personal use only WM 4500 MZL MZL 1000 1200 $480M PCNSL 1500 DLBCL/HGBCL DLBCL/HGBCL WM DLBCL/HGBCL WM
Slide 10: Azer-cel in DLBCL
For personal use only Azer-cel in DLBCL 10 10
Slide 11: Azer-cel has shown 82% Overall Response Rate in DLBCL patients
Azer-cel has shown 82% Overall Response Rate in DLBCL patients Azer-cel has delivered promising results in 3L+ DLBCL CAR-T relapsed patients FINDINGS For personal use only • 82% Overall Response Rate (14/17 evaluable patients) observed in relapsed/refractory DLBCL patients who had failed prior autol
Slide 12: Compelling Cohort 1 Phase 1b data in DLBCL to date
Compelling Cohort 1 Phase 1b data in DLBCL to date 82% Overall Response Rate in Relapsed/Refractory (R/R) DLBCL Cohort 1 of the Phase 1b study evaluates azer-cel in heavily pre-treated 3L+ patients with R/R DLBCL, including patients who have failed prior autologous CAR-T therapy For personal use onl
Slide 13: Azer-cel compared to existing Approved Auto CAR-T Therapies
Azer-cel compared to existing Approved Auto CAR-T Therapies Initial azer-cel Ph 1b R/R DLBCL data is compelling when compared to approved Auto CAR-T treatments For personal use only Azer-cel is comparable to approved Auto CAR-Ts for treatment of DLBCL 2L+ of therapy1 82% 74% 73% Overall 52% Despite
Slide 14: Patient Case Study: Cancer Free for 22+ months
Patient Case Study: Cancer Free for 22+ months Complete Response for an azer-cel patient that failed 4 prior lines of therapy including autologous CAR-T. Durability of Response now out to 22+ months and patient currently remains cancer free Tumor Tumor-free For personal use only Baseline Day 365 PAT
Slide 15: Azer-cel Registrational Opportunity
For personal use only Azer-cel Registrational Opportunity 15 15
Slide 16: Cohort 2: CAR-T naïve patients show strong response in CLL and MZL
Cohort 2: CAR-T naïve patients show strong overall response rate of 100% in CLL and 80% in MZL Cohort 2: Evaluates azer-cel in CAR-T naïve patients KEY TAKEAWAYS across rare and niche lymphomas For personal use only • Limited treatment options and no approved CAR-T Evaluable Overall Response therapi
Slide 17: Cohort 2: CAR T Naïve Subset Indication
Cohort 2: CAR T Naïve Subset Indication Imugene’s Cohort 2 has delivered impressive early results with a 100% ORR in CLL (4/4) and 80% ORR in MZL (4/5) For personal use only Marginal Zone Lymphoma (MZL) Chronic/Small Lymphocytic Leukemia (CLL/SLL) 80% ORR 100% ORR • In CLL/SLL, CRs are uncommon and
Slide 18: Cohort 3: BTKi + azer-cel combination
Cohort 3: BTKi + azer-cel combination Combination Supports Expanded Registrational and Commercial Opportunity For personal use only BTK inhibitors are an established standard of care across multiple B-cell malignancies and when combined with azer-cel, BTKis: • Enhance CAR-T cell fitness and durabili
Slide 19: BTKi Market is Large and Growing
BTKi Market is Large and Growing Combination with existing BTKi’s to increase registrational and commercial opportunity For personal use only • BTK inhibitors are an established standard of care across multiple B-cell malignancies with >US$10bn in annual global sales BTKi Drug Annual Revenue Contrib
Slide 20: Proposed Clinical Pathway: Azer-cel Allogeneic CD19 CAR-T 2026 Execution
Proposed Clinical Pathway: Azer-cel Allogeneic CD19 CAR-T 2026 Execution 2026 Provides Opportunity to Progress Toward Registrational Strategy Clinical Manufacturing & Supply For personal use only • Continued enrollment and • Scale-up and validation of • Continue advancement of azer-cel across Cohort
Slide 21: Key Achievements & Expected Upcoming Milestones
Key Achievements & Expected Upcoming Milestones Recent Key Achievements Expected Upcoming Milestones January 2025: First Aus site opened for R/R Calendar Year 2026-2027 DLBCL clinical trial and first DLBCL patient • Regular and ongoing Phase 1b data on For personal use only dosed in AUS CAR-T naïve
Slide 22: Experienced Leadership Team and BoD
Experienced Leadership Team and BoD has brought FDA-Approved Drugs to Market Executive Management Team For personal use only Leslie Chong John Byon, MD, PhD Ursula McCurry Darren Keamy Chief Executive Officer Chief Medical Chief Clinical Chief Financial Officer & & Managing Director Officer Operatio
Slide 23: Offer Details
For personal use only Offer Details 2323
Slide 24: Capital Raising Summary
Capital Raising Summary Non-underwritten two-tranche placement (Placement) of up to A$12.0 million, comprising the issue of up to 66.7 million new fully paid ordinary shares (New Shares) PLACEMENT Tranche 1 to raise A$6.4 million, utilising the Company’s available placement capacity under ASX Li
Slide 25: Sources & Uses
Sources & Uses Offer proceeds to be used to continue the ongoing development of azer-cel through the expansion of Cohort 2 and the new Cohort 3 (BTKi) of its Phase 1b trial, giving the Company cash runway into Q4 CY20261 • Offer proceeds of A$20 million adds to the existing pro forma For personal us
Slide 26: Timetable
Timetable EVENT DATE (2026) Trading Halt Tuesday 10, March For personal use only Placement bookbuild Tuesday, 10 March Record Date for SPP 7.00pm (AEDT) Tuesday, 10 March Results of Placement announced & Imugene resumes trading on ASX Wednesday, 11 March Settlement of New Shares issued under Tranche
Slide 27: Key Risk Factors
Key Risk Factors Specific investment risks unable to find a partner, it would be required to develop and commercialise potential products at its own expense. This may place significant demands on the Company’s • IMU’s products in development and not approved for commercial sale – Investment internal
Slide 28: Key Risk Factors
Key Risk Factors General investment risks statements can be identified by the use of forward-looking terminology such as, but not limited to, ‘may’, ‘will’, ‘expect’, ‘anticipate’, ‘estimate’, ‘would be’, ‘believe’, or • Investment risks - The price of the Shares might rise or fall and they might tr
Slide 29: Foreign Offer Restrictions
Foreign Offer Restrictions This presentation is for information purposes only and is not an invitation or offer of securities in New Zealand (or allotted with a view to being offered for sale in New securities for subscription, purchase or sale in any jurisdiction. The distribution of this Zealand)
Slide 30: Summary of Terms – Convertible Note Amendment
Summary of Terms – Convertible Note Amendment 1. Ongoing support from key investor Heights Capital Management, Inc (and its affiliate CVI Investments, Inc.) For personal use only 2. HCM intends to participate in the Placement 3. CVI have agreed to amendment of existing Convertible Note Facility 4. E
Slide 31: For personal use only
ASX : IMU imugene.com For personal use only Connect with us on LinkedIn @Imugene Limited Follow us on X (Twitter) @TeamImugene Watch us on YouTube @ImugeneLimited 31 31